Valuation
- Market cap
- 4,499,006,000
- Revenue TTM
- $0
- Net income TTM
- $-252,060,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 15,312,200
- Avg volume
- 2,915,698
- Day's range
- $54.37 – $54.83
- Shares out
- 82,324,000
- Stochastic %K
- 67%
- Beta
- -0.40
- Analysts
- Hold
- Price target
- $56.67
Company profile
Akero Therapeutics, Inc. engages in developing transformational treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of metabolic dysfunction-associat...
Show more
Akero Therapeutics, Inc. engages in developing transformational treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Therapeutics, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California. As of December 9, 2025, Akero Therapeutics, Inc. operates as a subsidiary of Novo Nordisk A/S.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 650 487 6488
- Website
- https://akerotx.com
- Address
- 601 Gateway Boulevard, Suite 350, South San Francisco, United States
Latest news
No headlines yet.
